244 related articles for article (PubMed ID: 31553876)
21. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
[TBL] [Abstract][Full Text] [Related]
22. Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.
Hu Z; Zhang D; Hao J; Tian K; Wang W; Lou H; Yuan H
Cancer Chemother Pharmacol; 2014 Feb; 73(2):397-407. PubMed ID: 24322375
[TBL] [Abstract][Full Text] [Related]
23. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.
Ewald JA; Desotelle JA; Church DR; Yang B; Huang W; Laurila TA; Jarrard DF
Prostate; 2013 Mar; 73(4):337-45. PubMed ID: 22911222
[TBL] [Abstract][Full Text] [Related]
25. Secreted frizzled-related protein 5 suppresses aggressive phenotype and reverses docetaxel resistance in prostate cancer.
Xu Q; Lü Z; Wang X; Zhu Q; Wu H
J Investig Med; 2019 Aug; 67(6):1009-1017. PubMed ID: 30787036
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Ogura T; Tanaka Y; Tamaki H; Harada M
Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
[TBL] [Abstract][Full Text] [Related]
27. Argentatin B Inhibits Proliferation of Prostate and Colon Cancer Cells by Inducing Cell Senescence.
Alcántara-Flores E; Brechú-Franco AE; García-López P; Rocha-Zavaleta L; López-Marure R; Martínez-Vázquez M
Molecules; 2015 Nov; 20(12):21125-37. PubMed ID: 26633316
[TBL] [Abstract][Full Text] [Related]
28. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
29. Anti-cancer effect of marchantin C via inducing lung cancer cellular senescence associated with less secretory phenotype.
Zhang XL; Ji XT; Sun B; Qian LL; Hu XL; Lou HX; Yuan HQ
Biochim Biophys Acta Gen Subj; 2019 Oct; 1863(10):1443-1457. PubMed ID: 31103748
[TBL] [Abstract][Full Text] [Related]
30. In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells.
Jia L; Yu W; Wang P; Sanders BG; Kline K
Prostate; 2008 Jun; 68(8):849-60. PubMed ID: 18324647
[TBL] [Abstract][Full Text] [Related]
31. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
32. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic adenovirus carrying SPAG9-shRNA enhanced the efficacy of docetaxel for advanced prostate cancer.
Lu M; Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Wu C; Mao L
Anticancer Drugs; 2022 Feb; 33(2):142-148. PubMed ID: 34561997
[TBL] [Abstract][Full Text] [Related]
34. A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.
Li H; Zhang W; Zhao K; Zhao D; Zheng S; Hu Y
J Biol Chem; 2020 Mar; 295(12):4049-4063. PubMed ID: 32005663
[TBL] [Abstract][Full Text] [Related]
35. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
36. 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway.
Zhang F; Li M; Wu X; Hu Y; Cao Y; Wang X; Xiang S; Li H; Jiang L; Tan Z; Lu W; Weng H; Shu Y; Gong W; Wang X; Zhang Y; Shi W; Dong P; Gu J; Liu Y
Drug Des Devel Ther; 2015; 9():3969-87. PubMed ID: 26309394
[TBL] [Abstract][Full Text] [Related]
37. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
38. Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line.
Cancino-Marentes ME; Hernández-Flores G; Ortiz-Lazareno PC; Villaseñor-García MM; Orozco-Alonso E; Sierra-Díaz E; Solís-Martínez RA; Cruz-Gálvez CC; Bravo-Cuellar A
BMC Urol; 2021 Mar; 21(1):38. PubMed ID: 33711972
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
Fu W; Hong Z; You X; Din J; Chen B; Zhao B; Yuan G; Li Q
Biomed Pharmacother; 2019 Oct; 118():109374. PubMed ID: 31545228
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
